flâneur

Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate - PMC

ncbi.nlm.nih.gov · 2,817 words · saved by 1 readers

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 1HIV and AIDS Malignancy Branch, 1HIV and AIDS Malignancy Branch, 1HIV and AIDS Malignancy Branch, 1HIV and AIDS Malignancy Branch, 1HIV and AIDS Malignancy Branch, 1HIV and AIDS Malignancy Branch, 2Biostatistics and Data Management Section, and 3Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; 3Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; 3Laboratory of Patho

TO THE EDITOR: HIV-associated primary central nervous system (CNS) lymphoma (HIV-PCNSL), an AIDS-defining malignancy, generally develops in patients with severe CD4+ T-cell lymphopenia. HIV-PCNSL encompasses a variety of CD20+ and usually Epstein Barr virus (EBV)–positive B-cell lymphoproliferative disorders, with a range of polymorphic and monomorphic morphologies.1-3 The World Health Organization classification also recognizes a form of primary diffuse large B-cell lymphoma of the CNS in patients without recognized immunodeficiencies that is usually EBV− and likely has a different natural…

saved by

related reading